Deutsche Bank Maintains a Buy Rating on Sanofi (SNY)

Sanofi (NASDAQ:SNY) is one of the best low volatility large cap stocks to invest in. Deutsche Bank analyst Emmanuel Papadakis maintained a Buy rating on Sanofi (NASDAQ:SNY) on November 25, setting a €110 price target.

Is Sanofi (SNY)the Best Gene-Editing Stock to Buy?

The same day, Sanofi (NASDAQ:SNY) announced the approval of Dupixent (dupilumab) by the European Commission for the treatment of “moderate-to-severe chronic spontaneous urticaria (CSU) in adult and adolescent patients 12 years and above with inadequate response to histamine-1 antihistamines (H1AH) and who are naive to anti-immunoglobulin-E (IgE) therapy for CSU”.

Management reported that Sanofi and Regeneron’s Dupixent can be used as a first-line targeted treatment option, and attained approval as the first targeted medicine in the EU in over a decade for chronic spontaneous urticaria.

Sanofi (NASDAQ:SNY) added that the approval was based on phase 3 studies that demonstrated a significant reduction in itch and hives at 24 weeks compared to placebo due to Dupixent.

Sanofi (NASDAQ:SNY) researches, produces, and distributes pharmaceutical products. The company’s operations are divided into the Pharmaceuticals, Consumer Healthcare, and Vaccines segments.

While we acknowledge the potential of SNY to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than SNY and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.